original ) (raw )Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease
Martin Bortlik
Journal of Crohn's and Colitis, 2013
View PDFchevron_right
Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s Disease
Renata Vilela
Clinical Gastroenterology and Hepatology, 2006
View PDFchevron_right
Changes in Serum Trough Levels of Infliximab During Treatment Intensification but not in Anti-infliximab Antibody Detection are Associated with Clinical Outcomes after Therapeutic Failure in Crohn's Disease
Klaus Bendtzen
Journal of Crohn's & colitis, 2015
View PDFchevron_right
Predictors of response to infliximab in patients with Crohn's disease
am parsy
Gastroenterology, 2002
View PDFchevron_right
Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response
Luis Abreu
Gastroenterología y hepatología
View PDFchevron_right
Factors associated with durable response to infliximab in Crohn's disease 5 years and beyond: a multicenter international cohort
Joshua Korzenik
Inflammatory bowel diseases, 2015
View PDFchevron_right
Long-term Durability of Infliximab Treatment in Crohn's Disease and Efficacy of Dose “Escalation” in Patients Losing Response
JUAN ANTONIO OBREGON MENDOZA
Journal of Clinical Gastroenterology, 2011
View PDFchevron_right
Need for infliximab dose intensification in Crohn's disease and ulcerative colitis
Enrique Rey
World journal of gastroenterology : WJG, 2014
View PDFchevron_right
Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience
Bruce Salzberg MD, FACG
Inflammatory Bowel Diseases, 2018
View PDFchevron_right
Infliximab in the treatment of Crohn's disease: Predictors of response in an Italian multicentric open study
Antonio Rispo
Digestive and Liver Disease, 2005
View PDFchevron_right
Infliximab De-escalation in Patients With Crohn’s Disease in Clinical Remission Is Safe and Well-tolerated
Matthew Hamilton
Inflammatory Bowel Diseases, 2021
View PDFchevron_right
Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions
Richard Kozarek
The American journal of gastroenterology, 2003
View PDFchevron_right
Clinical Experience with Infliximab for Crohn’s Disease: The First 100 Patients in Edmonton, Alberta
Mang Ma
Canadian Journal of Gastroenterology, 2002
View PDFchevron_right
Infliximab for Crohn's disease in clinical practice at the Mayo clinic: The first 100 patients
Cristina Toader
Gastroenterology, 2000
View PDFchevron_right
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
Ilse Hoffman
Gut, 2009
View PDFchevron_right
The safety profile of infliximab in patients with Crohn’s disease: The Mayo Clinic experience in 500 patients
Jean-frédéric Colombel
Gastroenterology, 2004
View PDFchevron_right
Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial
Klaus Bendtzen
BMJ Open, 2014
View PDFchevron_right
Retrieval of Serum Infliximab Level by Shortening the Maintenance Infusion Interval Is Correlated with Clinical Efficacy in Crohnʼs Disease
Satoshi Motoya
Inflammatory Bowel Diseases, 2012
View PDFchevron_right
Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn’s Disease
Ragna Vanslembrouck
Clinical Gastroenterology and Hepatology, 2020
View PDFchevron_right
Doubling the infliximab dose versus halving the infusion intervals in Crohnʼs disease patients with loss of response
Maria Abreu
Inflammatory Bowel Diseases, 2012
View PDFchevron_right